I NNOVATORS 2010 Sorafenib Brain Distribution is Restricted by BCRP-Mediated Efflux at the BBB Sagar Agarwal University of Minnesota.

Slides:



Advertisements
Similar presentations
Pharmacological P-gp identification Since P-gp mediated drug efflux is a major hurdle in CNS drug discovery, it is important to identify P-gp substrates.
Advertisements

Howard E. Gendelman, MD Larson Professor of Medicine and Infectious Diseases Chairman, Department of Pharmacology and Experimental Neuroscience Director,
Modern Tools for Drug Discovery NIMBUS Biotechnology Modern Tools for Drug Discovery
Multidrug Resistance (MDR) is one of the major reasons for anti-cancer chemotherapy failure. The molecular mechanisms of MDR in cancer cells are involved.
Abstract No. SAT0356 THE THERAPEUTIC EFFICACY OF THE NOVEL URICOSURIC AGENT UR-1102 FOR HYPERURICEMIA AND GOUT S. O. Ahn1, N. Horiba2*, S. Ohtomo2, K.
Cell culture models in the study of drug efflux transporters
Drug-Like Properties: Optimizing Pharmacokinetics and Safety During Drug Discovery Li Di and Edward H. Kerns ACS Short Course.
Background: Focus on P-gp Questions:
H. Koivunoro1, E. Hippelänen1, I. Auterinen2, L. Kankaanranta3, M
Bioavailability of Drugs with Nonlinear Pharmacokinetics (PK) Can be Approximated by the Ratio of Doses that Provide Equal Areas under the Concentration-Time.
INTRAVENOUS INFUSION.
Y OUNG I NNOVATORS 2009 Drug transport by genetic variants of the liver specific human organic transporter OCT1 (SLC22A1). Effect of concomitantly administered.
The General Concepts of Pharmacokinetics and Pharmacodynamics Hartmut Derendorf, PhD University of Florida.
Concepts and Applications of Pharmacokinetics
RESEARCH Lymphatic Targeting of Tenofovir; Intracellular Pharmacokinetics and Viral Dynamics Arnold Fridland, Ph.D, William Lee, Ph.D. Gilead Sciences,
Acknowledgement of funding Regulator of G-protein signaling 5 blunts cellular viability mediated by a stabilized lysophosphatidic acid analogue (2S-OMPT)
U N I V E R S I T Y O F K E N T U C K Y - C O L L E G E O F P H A R M A C Y Pharmacokinetics & Drug Transport Philip E. Empey, Pharm.D., Ph.D., BCPS Assistant.
Can cancer brain metastases be treated using humanized monoclonal antibodies: a pilot pharmacological study Guilhem BOUSQUET, Anne JANIN University Paris.
EC917 Eva Gallardo, MD Medical Manager, Biocompatibles UK Drug Eluting Bead: Future Product Applications.
Tamoxifen, Endoxifen, and CYP2D6 Sally Usdin Yasuda, MS, PharmD Senior Reviewer, Division of Clinical Pharmacology 1 Office of Clinical Pharmacology Center.
The Use of a Vesicular Delivery System in the Enhancement of Cisplatin Bioavailability Manal M. Alsaadi, Katharine C. Carter and Alexander B. Mullen Strathclyde.
Objective: To utilize preclinical and phase I PK/PD data from a new quinolone (Q) and relevant public domain data to develop an exposure-response model.
Proprietary Eisai Information. Cannot be reproduced in whole or in part without Eisai’s express written consent – Copyright 2009 Eisai Modeling of hypertension.
The impact of hemi-brain irradiation on accumulation of PI3K/mTOR inhibitors with limited (GDC-0980) and robust (GNE-317) blood-brain barrier penetration.
Macitentan – A novel sulfamide
The General Concepts of Pharmacokinetics and Pharmacodynamics
Multiple dosing: intravenous bolus administration
Final Efficacy Results from OAM4558g, a Randomized Phase II Study Evaluating MetMAb or Placebo in Combination with Erlotinib in Advanced NSCLC Spigel DR.
May 19, 2005FDA Antiviral Drugs Advisory Committee Meeting 1 Tipranavir NDA Drug Interactions Yuanchao (Derek) Zhang, Ph.D. Clinical Pharmacology.
Malaysia, EVALUTION OF DOSSIERS IN WHO- PREQUALIFICATION PROJECT MULTISOURCE TB-DRUGS Evaluation of bioavailability/bioequivalence data Based,
Design of Sustained Release Dosage Forms
Blood-Brain Barrier 강 경 태 Contents 1. BBB Fundamentals 2. Effects of Brain Penetration 3. Structure-BBB Penetration Relationships 4. Structure.
1 Transporters and Their Role in Drug Interactions.
Do We Need to Optimize Protein Binding in Drug Discovery? NEDMDG Summary Meeting Xingrong Liu, Ph.D. Genentech.
Pharmacokinetics (PK) and Pharmacodynamics (PD) of Rivaroxaban: A Comparison of Once- and Twice-daily Dosing in Patients Undergoing Total Hip Replacement.
Copyright © 2008 Merck & Co., Inc., Whitehouse Station, New Jersey, USA All rights Reserved Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Raltegravir.
Transporters Lee,Sang-Hwi. 9.1 Transporter Fundamentals Physicochemical properties lipophilicity hydrogen bonds M.W. Toxic xenobiotics (drugs)
01/22/2010 – 7:45pmeSlide – P6617 – MedImmune 4 x 8 Poster Template Detection of a human anti-PDGFR  therapeutic antibody in a human GBM orthotopic rat.
By : Dr. Roshini Murugupillai
Clinicaloptions.com/hepatitis Effect of Telaprevir on the Pharmacokinetics of Cyclosporine and Tacrolimus Slideset on: Garg V, van Heeswijk R, Lee JE,
(Journal of Biomedical and Clinical Sciences)
Understanding Cancer Drug Resistance by Developing and Studying Resistant Cell Line Models Xavier CP, Pesic M, Vasconcelos MH. Curr Cancer Drug.
Novel Transcription Factor Inhibitor as Treatment for Epithelial Cell Cancers John Bushweller, Department of Molecular Physiology and Biological Physics,
Epithelial-to-Mesenchymal Transitions Circulating Tumor Cells
Brain Barrier Research Center:
Apatinib (YN968D1) reverses multidrug resistance by inhibiting the function of multiple ATP-binding cassette transporters Yanjun Mi, Liwu Fu State Key.
in the Rat Pup Ultrasonic Vocalization Model
2Invictus Oncology Pvt. Ltd. New Delhi, India
Investigation of the effect of active efflux at the blood–brain barrier on the distribution of nonsteroidal aromatase inhibitors in the central nervous.
Epithelial-to-Mesenchymal Transitions Circulating Tumor Cells
iRGD, a tumor-penetrating peptide for tumor-specific drug delivery
Comparison of pantoprazole concentrations in
Pharmacokinetics: Drug Distribution and Drug Reservoirs
Epithelial-to-Mesenchymal Transitions Circulating Tumor Cells
Treatment with BLU9931 leads to tumor regression in the FGF19-overexpressing PDX-derived xenograft LIXC012. Treatment with BLU9931 leads to tumor regression.
Pharmacokinetics: Drug Distribution and Drug Reservoirs
Colby S. Shemesh, Rosie Z. Yu, Mark S
Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.
Nat. Rev. Clin. Oncol. doi: /nrclinonc
miR-124 Inhibits Lung Tumorigenesis Induced by K-ras Mutation and NNK
Effects of inhibitors of drug efflux pumps on the penetration of antibiotics into the central nervous system. Effects of inhibitors of drug efflux pumps.
Volume 25, Issue 7, Pages (July 2017)
Nanoemulsions as Versatile Formulations for Paclitaxel Delivery: Peroral and Dermal Delivery Studies in Rats  Sateesh Khandavilli, Ramesh Panchagnula 
S. Aday, R. Cecchelli, D. Hallier-Vanuxeem, M.P. Dehouck, L. Ferreira 
Gefitinib Enhances Cytotoxicities of Antimicrotubule Agents in Non–Small-Cell Lung Cancer Cells Exhibiting No Sensitizing Epidermal Growth Factor Receptor.
Abebe Genetu Bayih, PhD University of Gondar
MMAE resistance and intracellular accumulation.
Triglycerides and leptin transport.
Intraperitoneal (IP) and intravenous (IV) milk fat inhibits leptin transport. Intraperitoneal (IP) and intravenous (IV) milk fat inhibits leptin transport.
MYC expression is correlated with dasatinib sensitivity in cancer cell lines and in vivo. MYC expression is correlated with dasatinib sensitivity in cancer.
Presentation transcript:

I NNOVATORS 2010 Sorafenib Brain Distribution is Restricted by BCRP-Mediated Efflux at the BBB Sagar Agarwal University of Minnesota

A BSTRACT Purpose: It is well known that the ATP Binding Cassette (ABC) transporters p-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) limit drug transport across the blood-brain barrier (BBB). This objective of this study was to investigate the role of these two efflux systems in limiting the delivery of sorafenib to the brain. Methods: In vitro studies - Directional flux and intracellular accumulation studies were conducted in MDCKII cells that overexpressed P-gp or BCRP. In vivo studies - FVBn (wild-type) mice were administered an I.V. dose of 10 mg/kg sorafenib followed by collection of blood and brain different time points post dose. Alzet osmotic minipumps were used to administer sorafenib via a continuous intraperitoneal infusion and steady-state brain and plasma concentrations were determined in FVBn wildtype, Mdr1a/b (-/-), Bcrp1 (-/-) and Mdr1a/b (-/-) Bcrp1 (-/-) mice. Results: In vitro studies showed that sorafenib was an avid substrate for BCRP with an apparent Km of 5.6 nM. While sorafenib did not appear to be P-gp substrate, it inhibited P-gp with an IC 50 of 25 µM. In the study conducted in FVB wildtype mice, sorafenib concentrations in brain were significantly lower than the plasma concentrations at all time points. The ratio of the area under the curve (AUC) in brain to that in plasma was 0.06 demonstrating the restricted brain penetration of sorafenib. Steady-state brain-to-plasma ratio of sorafenib was approximately 0.1 in the wild-type mice. This ratio increased by ~ 4-fold in the Bcrp1 (-/-) mice and by ~10-fold in the Mdr1a/b (-/-) Bcrp1 (-/-) mice, confirming BCRP mediated efflux at the BBB. Absence of P-gp in the Mdr1a/b (-/-) mice did not result in any significant improvement in the brain partitioning of sorafenib, as expected from the in vitro transport experiments. Conclusion: These results show that delivery of sorafenib to the brain is significantly restricted due to active efflux at the BBB. BCRP appears to be the dominant transporter in limiting sorafenib transport across the BBB. This study highlights the importance of BCRP at the BBB and warrants further investigation into the mechanism by which P-gp and BCRP ‘cooperate’ at the blood-brain barrier to keep substrate drugs out of the brain. Young Innovators 2009

Sorafenib : A Multi-targeted Kinase Inhibitor for Glioma Young Innovators 2009 Glioma - a malignant brain tumor Median Survival months No effective treatment !! Sorafenib inhibits PDGFR and VEGFR Currently being evaluated for therapy in glioma Efficient drug delivery to brain (tumor) essential for therapeutic efficacy

O BJECTIVE Young Innovators 2009 Study the interaction of sorafenib with p-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) Examine the effect of this interaction on distribution of sorafenib to the brain

M ATERIALS AND M ETHODS – I N V ITRO Invitro Studies – Intracellular Accumulation – Transcellular Flux MDCKII Cells – MDR1 Overexpressing – Bcrp1 Overexpressing Young Innovators 2009 Apical Basolateral MDCKII Cells

M ATERIALS AND M ETHODS – I N V IVO Young Innovators Genetic knockouts Mdr1a/b (-/-) [ P-gp knockout] Bcrp1 (-/-) [BCRP knockout] Mdr1a/b (-/-) Bcrp (-/-) Pharmacological Inhibitors Elacridar (GF120918) Dual P-gp/BCRP inhibitor Intravenous Drug Administration Blood and Brain Collection by Sparse Sampling Steady-State Pharmacokinetics Constant Rate Infusion brain Concentrationtime Concentrationtime

I NTERACTION OF S ORAFENIB WITH P- GP AND BCRP Young Innovators 2009 High affinity substrate for BCRP – Apparent Km of ~ 5 nM Not efficiently transported by P-gp Inhibits P-gp mediated transport – IC 50 ~ 25 µM No inhibitory effect on BCRP mediated transport of prazosin or mitoxantrone

Limited Sorafenib Transport to the Brain 8 FVB WT MICE Sorafenib transport to brain is restricted by the BBB 10 mg/kg i.v. dose Agarwal et al., October 2010, JPET t ½ = 1.6 hrs AUC brain /AUC plasma = 0.06

BCRP-Mediated Efflux Predominant at the BBB 9 Constant rate infusion of 2 mg/hr/kg into the peritoneal cavity Blood and brain sampled at 48 hours (4X) (10X) Agarwal et al., October 2010, JPET ?

Elacridar Increases B/P Ratio in the Knockouts 10 BCRP and P-gp together limit brain distribution Agarwal et al., October 2010, JPET 10 mg/kg i.v. dose, 1 hr timepoint

P-gp – BCRP Cooperation at the BBB 11 Polli et al., DMD, 2008 Agarwal et al., JPET, 2010 Lapatinib Gefitinib Dasatinib Chen et al., JPET, 2009 Sorafenib P-gp BCRP Agarwal et al., October 2010, JPET

12 Contribution of P-gp and BCRP to the total clearance out of brain

Efflux Clearance due to P-gp and BCRP 13 Kodaira H. et al., JPET 2010 PS BCRP = 7.5 Solving the three equations, by setting PS l,eff = 1 PS l,eff = 1 PS Pgp = 1.5 P-gp Knockout BCRP Knockout Triple Knockout R

LOG (100 – BEI) % Brain Efflux Index Method 14 Kakee et al., JPET 1996 Time after injection Slope = k efflux

Brain Efflux Index of Sorafenib 15 Triple Knockout BCRP Knockout P-gp Knockout Wild-type K out = 0.049/min K out = 0.104/min K out = 0.157/min K out = 0.145/min

16 Mice K out (min -1 ) t 1/2 (min) K out (min -1 ) Fold Increase Wild Type P-gp Knockout BCRP = BCRP Knockout Pgp = Triple Knockout P l, eff = Brain Efflux Index of Sorafenib Efflux rate constant correlates with brain partitioning BCRP is the dominant transporter compared to P-gp in effluxing sorafenib out of brain

Summary In vitro : Sorafenib is an avid BCRP substrate Transport of sorafenib across the BBB is restricted by BCRP and P-gp mediated active efflux The contribution of BCRP to the total efflux clearance is greater than that of P-gp P-gp and BCRP work together at the BBB significantly limiting delivery of dual substrates to the brain Delivery of Sorafenib to the brain can be an important determinant of its efficacy against brain tumors 17

Acknowledgements Eli Lilly & Co., AAPS PPDM Section Dr. William Elmquist Dr. John Ohlfest (University of Minnesota) Elmquist Lab – Dr. Li Li, Tianli Wang, Ramola Sane, Rajneet Oberoi NIH-NCI Grant CA Children’s Cancer Research Fund Doctoral Dissertation Fellowship, University of Minnesota Dr. Ronald Sawchuk Fellowship in Pharmacokinetics, UMN Dr. Edward Rippie Scholarship in Pharmaceutics, UMN 18

C ONTACT INFO Sagar Agarwal Ph.D. Candidate Department of Pharmaceutics, University of Minnesota Major: Pharmacokinetics, Pharmacodynamics. Advisor: Dr. William F. Elmquist Address: Weaver Densford Hall, 308 Harvard Street SE, Minneapolis, MN Young Innovators 2009